Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.74
BMY's Cash to Debt is ranked lower than
67% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. BMY: 0.74 )
Ranked among companies with meaningful Cash to Debt only.
BMY' s 10-Year Cash to Debt Range
Min: 0.32  Med: 0.92 Max: 2.26
Current: 0.74
0.32
2.26
Equity to Asset 0.47
BMY's Equity to Asset is ranked lower than
72% of the 562 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. BMY: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
BMY' s 10-Year Equity to Asset Range
Min: 0.33  Med: 0.45 Max: 0.55
Current: 0.47
0.33
0.55
Interest Coverage 12.76
BMY's Interest Coverage is ranked lower than
78% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2065.49 vs. BMY: 12.76 )
Ranked among companies with meaningful Interest Coverage only.
BMY' s 10-Year Interest Coverage Range
Min: 4.67  Med: 16.64 Max: 50.72
Current: 12.76
4.67
50.72
F-Score: 7
Z-Score: 6.34
M-Score: -2.09
WACC vs ROIC
8.56%
5.14%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 16.96
BMY's Operating margin (%) is ranked higher than
76% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. BMY: 16.96 )
Ranked among companies with meaningful Operating margin (%) only.
BMY' s 10-Year Operating margin (%) Range
Min: 10.45  Med: 26.25 Max: 31.29
Current: 16.96
10.45
31.29
Net-margin (%) 10.93
BMY's Net-margin (%) is ranked higher than
68% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. BMY: 10.93 )
Ranked among companies with meaningful Net-margin (%) only.
BMY' s 10-Year Net-margin (%) Range
Min: 9.19  Med: 16.39 Max: 56.42
Current: 10.93
9.19
56.42
ROE (%) 11.78
BMY's ROE (%) is ranked higher than
65% of the 685 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.19 vs. BMY: 11.78 )
Ranked among companies with meaningful ROE (%) only.
BMY' s 10-Year ROE (%) Range
Min: 13.25  Med: 28.02 Max: 78.36
Current: 11.78
13.25
78.36
ROA (%) 5.38
BMY's ROA (%) is ranked higher than
59% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BMY: 5.38 )
Ranked among companies with meaningful ROA (%) only.
BMY' s 10-Year ROA (%) Range
Min: 5.54  Med: 11.58 Max: 35.08
Current: 5.38
5.54
35.08
ROC (Joel Greenblatt) (%) 58.06
BMY's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.97 vs. BMY: 58.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BMY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 45.71  Med: 81.87 Max: 155.17
Current: 58.06
45.71
155.17
Revenue Growth (3Y)(%) -8.40
BMY's Revenue Growth (3Y)(%) is ranked lower than
84% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. BMY: -8.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BMY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -8.4  Med: 2.50 Max: 11.8
Current: -8.4
-8.4
11.8
EBITDA Growth (3Y)(%) -26.00
BMY's EBITDA Growth (3Y)(%) is ranked lower than
86% of the 483 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. BMY: -26.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BMY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -26  Med: 1.60 Max: 21.5
Current: -26
-26
21.5
EPS Growth (3Y)(%) -17.80
BMY's EPS Growth (3Y)(%) is ranked lower than
76% of the 451 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. BMY: -17.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BMY' s 10-Year EPS Growth (3Y)(%) Range
Min: -22.9  Med: -2.10 Max: 30.7
Current: -17.8
-22.9
30.7
» BMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

BMY Guru Trades in Q3 2014

Ray Dalio 10,228 sh (New)
Dodge & Cox 90,428 sh (+14.58%)
Vanguard Health Care Fund 38,480,761 sh (+6.31%)
Mario Gabelli 700,255 sh (+3.79%)
Brian Rogers 6,264,800 sh (+3.30%)
Ken Fisher 51,201 sh (+2.95%)
Bill Frels 294,435 sh (+0.31%)
Kahn Brothers 27,650 sh (unchged)
First Eagle Investment 14,492 sh (unchged)
Jeff Auxier 5,043 sh (unchged)
Pioneer Investments 84,994 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Murray Stahl 62,942 sh (-0.05%)
Ronald Muhlenkamp 212,485 sh (-0.13%)
Jeremy Grantham 1,520,723 sh (-16.53%)
Paul Tudor Jones 14,869 sh (-57.16%)
Jim Simons 270,900 sh (-88.98%)
» More
Q4 2014

BMY Guru Trades in Q4 2014

Steven Cohen 246,400 sh (New)
Ruane Cunniff 3,670 sh (New)
Jim Simons 298,500 sh (+10.19%)
Kahn Brothers 28,400 sh (+2.71%)
Vanguard Health Care Fund 39,056,361 sh (+1.50%)
Mario Gabelli 709,715 sh (+1.35%)
Dodge & Cox 91,028 sh (+0.66%)
Bill Frels 295,035 sh (+0.20%)
Jeff Auxier 5,043 sh (unchged)
Brian Rogers 6,264,800 sh (unchged)
First Eagle Investment 14,492 sh (unchged)
Paul Tudor Jones Sold Out
Ray Dalio Sold Out
Ronald Muhlenkamp 212,290 sh (-0.09%)
Murray Stahl 62,817 sh (-0.20%)
Pioneer Investments 84,466 sh (-0.62%)
Ken Fisher 30,739 sh (-39.96%)
Jeremy Grantham 10,762 sh (-99.29%)
» More
Q1 2015

BMY Guru Trades in Q1 2015

Louis Moore Bacon 60,000 sh (New)
Paul Tudor Jones 164,515 sh (New)
Steven Cohen 620,900 sh (+151.99%)
Jim Simons 474,100 sh (+58.83%)
Vanguard Health Care Fund 42,902,031 sh (+9.85%)
Ken Fisher 32,441 sh (+5.54%)
Pioneer Investments 87,155 sh (+3.18%)
Kahn Brothers 28,400 sh (unchged)
First Eagle Investment 14,492 sh (unchged)
Jeff Auxier 5,043 sh (unchged)
Paul Tudor Jones 350,000 sh (unchged)
Ruane Cunniff 3,670 sh (unchged)
Ronald Muhlenkamp 212,170 sh (-0.06%)
Bill Frels 293,770 sh (-0.43%)
Mario Gabelli 704,425 sh (-0.75%)
Dodge & Cox 87,828 sh (-3.52%)
Brian Rogers 5,814,800 sh (-7.18%)
Murray Stahl 56,017 sh (-10.83%)
Jeremy Grantham 8,110 sh (-24.64%)
» More
Q2 2015

BMY Guru Trades in Q2 2015

Ken Fisher 34,636 sh (+6.77%)
Kahn Brothers 28,800 sh (+1.41%)
Brian Rogers 5,814,800 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP1162.460.17$2.00 Convertible Preferred Stock

Guru Investment Theses on Bristol-Myers Squibb Company

Vanguard Health Care Fund Comments on Bristol-Myers Squibb Company - Mar 27, 2015

We increased our position in this biopharmaceutical company. We see its immuno-oncology franchise as a transformative driver in the years ahead and believe the market does not fully recognize the magnitude of the company’s potential in this area. Bristol-Myers Squibb (BMY) was the fund’s largest holding at the end of the period.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Bristol-Myers Squibb Company

Vanguard Adds to Four of Its Largest Stakes
It isn’t surprising that nearly 95% of Vanguard Health Care Fund (Trades, Portfolio)’s holdings are related to health care, drug manufacturing and medical technology. But there has been some jockeying for position within the Fund’s portfolio in the early months of 2015. Read more...
Vanguard Health Care Fund Comments on Bristol-Myers Squibb Company
We increased our position in this biopharmaceutical company. We see its immuno-oncology franchise as a transformative driver in the years ahead and believe the market does not fully recognize the magnitude of the company’s potential in this area. Bristol-Myers Squibb (BMY) was the fund’s largest holding at the end of the period. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 60.61
BMY's P/E(ttm) is ranked lower than
73% of the 472 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.90 vs. BMY: 60.61 )
Ranked among companies with meaningful P/E(ttm) only.
BMY' s 10-Year P/E(ttm) Range
Min: 4.05  Med: 19.65 Max: 64.88
Current: 60.61
4.05
64.88
Forward P/E 28.17
BMY's Forward P/E is ranked lower than
60% of the 233 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.27 vs. BMY: 28.17 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 61.70
BMY's PE(NRI) is ranked lower than
73% of the 472 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.00 vs. BMY: 61.70 )
Ranked among companies with meaningful PE(NRI) only.
BMY' s 10-Year PE(NRI) Range
Min: 12.26  Med: 20.24 Max: 64.76
Current: 61.7
12.26
64.76
P/B 7.14
BMY's P/B is ranked lower than
76% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. BMY: 7.14 )
Ranked among companies with meaningful P/B only.
BMY' s 10-Year P/B Range
Min: 2.46  Med: 4.13 Max: 7.64
Current: 7.14
2.46
7.64
P/S 6.62
BMY's P/S is ranked lower than
72% of the 649 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.43 vs. BMY: 6.62 )
Ranked among companies with meaningful P/S only.
BMY' s 10-Year P/S Range
Min: 1.63  Med: 2.66 Max: 7.09
Current: 6.62
1.63
7.09
PFCF 68.82
BMY's PFCF is ranked lower than
64% of the 275 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.38 vs. BMY: 68.82 )
Ranked among companies with meaningful PFCF only.
BMY' s 10-Year PFCF Range
Min: 7.44  Med: 19.50 Max: 141.78
Current: 68.82
7.44
141.78
POCF 50.16
BMY's POCF is ranked lower than
69% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.86 vs. BMY: 50.16 )
Ranked among companies with meaningful POCF only.
BMY' s 10-Year POCF Range
Min: 6.95  Med: 14.26 Max: 53.71
Current: 50.16
6.95
53.71
EV-to-EBIT 41.47
BMY's EV-to-EBIT is ranked lower than
70% of the 486 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.52 vs. BMY: 41.47 )
Ranked among companies with meaningful EV-to-EBIT only.
BMY' s 10-Year EV-to-EBIT Range
Min: 6.4  Med: 12.60 Max: 105
Current: 41.47
6.4
105
Shiller P/E 27.89
BMY's Shiller P/E is ranked higher than
65% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.83 vs. BMY: 27.89 )
Ranked among companies with meaningful Shiller P/E only.
BMY' s 10-Year Shiller P/E Range
Min: 10.15  Med: 13.92 Max: 29.87
Current: 27.89
10.15
29.87
Current Ratio 1.76
BMY's Current Ratio is ranked lower than
63% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. BMY: 1.76 )
Ranked among companies with meaningful Current Ratio only.
BMY' s 10-Year Current Ratio Range
Min: 1.13  Med: 1.61 Max: 2.32
Current: 1.76
1.13
2.32
Quick Ratio 1.58
BMY's Quick Ratio is ranked lower than
52% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. BMY: 1.58 )
Ranked among companies with meaningful Quick Ratio only.
BMY' s 10-Year Quick Ratio Range
Min: 0.93  Med: 1.32 Max: 2.07
Current: 1.58
0.93
2.07
Days Inventory 143.45
BMY's Days Inventory is ranked lower than
65% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.49 vs. BMY: 143.45 )
Ranked among companies with meaningful Days Inventory only.
BMY' s 10-Year Days Inventory Range
Min: 84.37  Med: 124.47 Max: 204.87
Current: 143.45
84.37
204.87
Days Sales Outstanding 56.66
BMY's Days Sales Outstanding is ranked higher than
64% of the 592 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.86 vs. BMY: 56.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMY' s 10-Year Days Sales Outstanding Range
Min: 35.38  Med: 65.73 Max: 82.36
Current: 56.66
35.38
82.36

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.28
BMY's Dividend Yield is ranked higher than
74% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. BMY: 2.28 )
Ranked among companies with meaningful Dividend Yield only.
BMY' s 10-Year Dividend Yield Range
Min: 2.12  Med: 4.45 Max: 7.07
Current: 2.28
2.12
7.07
Dividend Payout 1.38
BMY's Dividend Payout is ranked higher than
70% of the 393 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. BMY: 1.38 )
Ranked among companies with meaningful Dividend Payout only.
BMY' s 10-Year Dividend Payout Range
Min: 0.08  Med: 0.61 Max: 46.25
Current: 1.38
0.08
46.25
Dividend growth (3y) 2.90
BMY's Dividend growth (3y) is ranked lower than
61% of the 253 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. BMY: 2.90 )
Ranked among companies with meaningful Dividend growth (3y) only.
BMY' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 3.10 Max: 11.4
Current: 2.9
0
11.4
Yield on cost (5-Year) 2.64
BMY's Yield on cost (5-Year) is ranked higher than
69% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. BMY: 2.64 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BMY' s 10-Year Yield on cost (5-Year) Range
Min: 2.46  Med: 5.16 Max: 8.2
Current: 2.64
2.46
8.2
Share Buyback Rate 0.90
BMY's Share Buyback Rate is ranked higher than
89% of the 463 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.00 vs. BMY: 0.90 )
Ranked among companies with meaningful Share Buyback Rate only.
BMY' s 10-Year Share Buyback Rate Range
Min: 5.1  Med: 0.50 Max: -0.3
Current: 0.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 16.43
BMY's Price/Tangible Book is ranked lower than
91% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.32 vs. BMY: 16.43 )
Ranked among companies with meaningful Price/Tangible Book only.
BMY' s 10-Year Price/Tangible Book Range
Min: 4.91  Med: 12.84 Max: 53.3
Current: 16.43
4.91
53.3
Price/Projected FCF 2.20
BMY's Price/Projected FCF is ranked higher than
61% of the 321 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. BMY: 2.20 )
Ranked among companies with meaningful Price/Projected FCF only.
BMY' s 10-Year Price/Projected FCF Range
Min: 1.13  Med: 1.57 Max: 4.53
Current: 2.2
1.13
4.53
Price/Median PS Value 2.49
BMY's Price/Median PS Value is ranked lower than
81% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. BMY: 2.49 )
Ranked among companies with meaningful Price/Median PS Value only.
BMY' s 10-Year Price/Median PS Value Range
Min: 0.73  Med: 1.13 Max: 3.22
Current: 2.49
0.73
3.22
Price/Graham Number 6.57
BMY's Price/Graham Number is ranked lower than
86% of the 366 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. BMY: 6.57 )
Ranked among companies with meaningful Price/Graham Number only.
BMY' s 10-Year Price/Graham Number Range
Min: 1.41  Med: 3.70 Max: 7.03
Current: 6.57
1.41
7.03
Earnings Yield (Greenblatt) (%) 2.45
BMY's Earnings Yield (Greenblatt) (%) is ranked higher than
52% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. BMY: 2.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BMY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1  Med: 7.90 Max: 15.7
Current: 2.45
1
15.7
Forward Rate of Return (Yacktman) (%) -15.12
BMY's Forward Rate of Return (Yacktman) (%) is ranked lower than
86% of the 308 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.88 vs. BMY: -15.12 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BMY' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -15.3  Med: 5.40 Max: 27.5
Current: -15.12
-15.3
27.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BMY.Mexico, BRM.Germany, BMY.Argentina, BMYMP.USA, BMYB34.Brazil, 0R1F.UK, BMY.Switzerland,
Bristol-Myers Squibb Co is a Delaware corporation and was incorporated in August 1933 under the name Bristol-Myers Company. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. It is a biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in one segment: Biopharmaceuticals. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes called 'biologics'. These products are sold mainly to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. The Company's products include, Plavix, Avapro, Eliquis, Reyataz, Sustiva Franchise, Baraclude, Sprycel, Yervoy, Orencia among others. The Company promotes its products to healthcare providers such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the U.S. through direct-to-consumer print, radio and television and digital advertising and promotion. The markets in which the Company competes are generally broad-based and competitive. The Company competes with other research-based drug companies, research companies and generic drug manufacturers. The Company is subject to regulation by regional, country, state and local agencies.
» More Articles for BMY

Headlines

Articles On GuruFocus.com
Will Bill Ackman Go After Express Scripts Next? Jun 30 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
gild Jun 02 2015 
Abbvie Inc. Dividend Stock Analysis May 26 2015 
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 
Bristol-Myers Signs An Exclusive Pact In Gene Therapy For Treating Cardiovascular Disorders Apr 08 2015 
Piper Jaffray Sees Potential in uniQure NV (QURE) and Bristol-Myers Squibb (BMY) Collaboration Apr 07 2015 

More From Other Websites
Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying... Jul 29 2015
Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying... Jul 29 2015
Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying... Jul 29 2015
BRISTOL MYERS SQUIBB CO Financials Jul 29 2015
Bristol-Myers Squibb Co. Earnings Analysis: By the Numbers Jul 29 2015
Abbott Laboratories Earnings Analysis: By the Numbers Jul 29 2015
Gilead beats Street 2Q forecasts on surge in sales, profit Jul 28 2015
Gilead beats Street 2Q forecasts on surge in sales, profit Jul 28 2015
Drugmaker Pfizer tops Street 2Q forecasts, raises forecast Jul 28 2015
Drugmaker Pfizer tops Street 2Q forecasts, raises forecast Jul 28 2015
European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo... Jul 28 2015
Short Sellers Run For Cover From Major Pharma Jul 27 2015
European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization... Jul 27 2015
7:01 am Bristol-Myers and AbbVie (ABBV) announce the European... Jul 27 2015
European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization... Jul 27 2015
10-Q for Bristol-Myers Squibb Co. Jul 25 2015
Bristol-Myers wins approval for 1st hepatitis C type 3 drug Jul 24 2015
Bristol-Myers wins approval for 1st hepatitis C type 3 drug Jul 24 2015
UPDATE 2-AbbVie, Bristol-Myers get FDA nod for hep C treatments Jul 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK